Molecure, formerly known as OncoArendi Therapeutics, is a biopharmaceutical company focused on developing therapeutics for neo-plastic, inflammatory diseases and fibrotic diseases.In March 2022, the company changed its name from OncoArendi Therapeutics to Molecure.In July 2023, Molecure SA completed a successful Secondary Public Offering of 2,776,000 series H shares by private placement, offered within the authorized capital, at an issue price of PLN 18 per share with gross proceeds of PLN 50 million (USD 12 million).In December 2017, the company filed for an initial public offering (IPO) of its shares on the Warsaw Stock Exchange's regulated market with the Financial Supervision Authority. At that time, the IPO was expected to initiate in first half of 2018.In October 2015, the company received over PLN 20 million (US $5.28 million) co-financing from European Funds for the CHIT-1 project with a budget of PLN 25.5 million (US $6.73 million).In August 2015, the compa